Nanoligent

Nanoligent is a spin-off of the UAB and the Institut de Recerca de l'Hospital de Santa Creu i Sant Pau specialised in nanotechnology-based cancer treatments based on the targeted elimination of cancer cells overexpressing the CXCR4 receptor, a biomarker of poor prognosis and resistance to standard therapy that is considered key in the development of metastasis. The company is developing a new proprietary nanotechnology platform with the potential to overcome the limitations of current treatments based on cytotoxic drug-antibody conjugates.